Wedbush Analyst David Nierengarten reiterated an Outperform rating with a 12-month price target of $1000 for argenx SE (ARGX), a commercial-stage biopharma company.
The company markets VYVGART or Efgartigimod for the treatment of generalised Myasthenia Gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.